FROM PUBLIC EVENTS · 2026-11-18

Current stage

  1. Discovery · preclinical
  2. Early clinical · first deals
  3. Late clinical · capacity
  4. Commercial · sales
  1. Global approvals · expansion
  2. M&A · integration
  3. Pipeline reshaping

Global approvals · expansion Earns most haemostat revenue from exports to the US, Europe and Japan while running a US approval trial for its embolic agent. Also seen: Early clinical · first deals

  • Disclosed record quarterly revenue for Q3 2026. Source
  • Announced the start of a next-generation haemostat project and a new embolic trial project. Source

Roles often seen at this stageDevice R&D & support · Regulatory affairs · Clinical & PV

Companies at the same stage and their people flow →

← Company library
Korea / Company briefSources checked 2026-11-18

Nextbiomedical

A developer of polymer medical devices and drug delivery technology that makes the Nexpowder endoscopic haemostat and Nexsphere embolic agents, earning about 97% of revenue overseas.

Nexpowder

Marketed

Powder endoscopic haemostat; cumulative sales to Q3 2026 were about KRW 11.9 billion, with exports split 51% US, 42% Europe and 7% Japan.

Nexsphere / Nexsphere-F

Marketed

Embolic agents whose cumulative sales to Q3 2026 rose 25% year on year; Nexsphere-F is in a clinical trial for US FDA approval.

Nexpowder T

Stage unconfirmed

A next-generation haemostat adding chemical coagulation to physical adhesion, to go through a Korean trial before a US FDA IDE application.

Announced

Started government-backed projects to develop the Nexpowder T haemostat and to test the Nexsphere-H embolic in musculoskeletal pain patients.

Official role guide

Nextbiomedical careers

Current availability unconfirmed

Observed 2026-11-18

Work
Unconfirmed — The official careers page could not be confirmed.
Experience & requirements
Unconfirmed — The official careers page could not be confirmed.

Information from a role guide does not establish a current vacancy.

Sources & coverage 2

A brief based on selected official material, not an exhaustive product or vacancy list.

  1. 넥스트바이오메디컬, 차세대 지혈 신제품 개발 착수…혈관색전 임상도 시작 ↗한국경제 · Published 2026-04-15 · Sources checked 2026-11-18 · Original unavailable
  2. 넥스트바이오메디컬, 3분기 역대 최대 분기 매출 기록 ↗머니투데이방송 · Published 2026-11-17 · Sources checked 2026-11-18 · Original unavailable